These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27427228)

  • 1. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
    Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
    Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
    Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
    J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
    Horton JR; Woodcock CB; Chen Q; Liu X; Zhang X; Shanks J; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Cyr M; Pohida K; Hu X; Shah P; Xu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Cheng X
    J Med Chem; 2018 Dec; 61(23):10588-10601. PubMed ID: 30392349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
    Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
    Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
    Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
    Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
    Jaikhan P; Buranrat B; Itoh Y; Chotitumnavee J; Kurohara T; Suzuki T
    Bioorg Med Chem Lett; 2019 May; 29(10):1173-1176. PubMed ID: 30928196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potent, selective KDM5 inhibitors.
    Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of KDM5A for cancer treatment.
    Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
    Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The KDM5 family of histone demethylases as targets in oncology drug discovery.
    Rasmussen PB; Staller P
    Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of KDM5A in human cancer.
    Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
    J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Proteolysis Targeting Chimeras (PROTACs) for Lysine Demethylase 5 and Their Neurite Outgrowth-Promoting Activity.
    Iida T; Itoh Y; Takahashi Y; Miyake Y; Zamani F; Yamashita Y; Takada Y; Akiyama T; Ibaraki J; Okuda K; Tokuda Y; Nishimura T; Hidaka K; Mori H; Oba M; Suzuki T
    Chem Pharm Bull (Tokyo); 2024; 72(7):638-647. PubMed ID: 38945940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of in vitro JMJD lysine demethylase candidate substrates via systematic determination of substrate preference.
    Hoekstra M; Biggar KK
    Anal Biochem; 2021 Nov; 633():114429. PubMed ID: 34678252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.
    Horton JR; Liu X; Wu L; Zhang K; Shanks J; Zhang X; Rai G; Mott BT; Jansen DJ; Kales SC; Henderson MJ; Pohida K; Fang Y; Hu X; Jadhav A; Maloney DJ; Hall MD; Simeonov A; Fu H; Vertino PM; Yan Q; Cheng X
    J Med Chem; 2018 Apr; 61(7):3193-3208. PubMed ID: 29537847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
    Labadie SS; Dragovich PS; Cummings RT; Deshmukh G; Gustafson A; Han N; Harmange JC; Kiefer JR; Li Y; Liang J; Liederer BM; Liu Y; Manieri W; Mao W; Murray L; Ortwine DF; Trojer P; VanderPorten E; Vinogradova M; Wen L
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4492-4496. PubMed ID: 27499454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
    Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
    Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
    Tumber A; Nuzzi A; Hookway ES; Hatch SB; Velupillai S; Johansson C; Kawamura A; Savitsky P; Yapp C; Szykowska A; Wu N; Bountra C; Strain-Damerell C; Burgess-Brown NA; Ruda GF; Fedorov O; Munro S; England KS; Nowak RP; Schofield CJ; La Thangue NB; Pawlyn C; Davies F; Morgan G; Athanasou N; Müller S; Oppermann U; Brennan PE
    Cell Chem Biol; 2017 Mar; 24(3):371-380. PubMed ID: 28262558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling.
    Longbotham JE; Chio CM; Dharmarajan V; Trnka MJ; Torres IO; Goswami D; Ruiz K; Burlingame AL; Griffin PR; Fujimori DG
    Nat Commun; 2019 Jan; 10(1):94. PubMed ID: 30626866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
    Liang J; Labadie S; Zhang B; Ortwine DF; Patel S; Vinogradova M; Kiefer JR; Mauer T; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; An L; Ran Y; Classon M; Trojer P; Dragovich PS; Murray L
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2974-2981. PubMed ID: 28512031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
    Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
    Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.